Key Points
- REGENXBIO insider Steve Pakola sold 2,161 shares on July 2 at an average price of $13.64, worth about $29,476. After the sale, he still held 213,009 shares.
- Pakola also made several recent larger sales, including 19,608 shares on June 29 and 36,725 shares on July 1, adding to a run of insider selling over the past few months.
- The company’s latest results were weak, with Q1 EPS of -$1.72 versus expectations of -$1.36 and revenue of $6.39 million, well below the $25.84 million consensus estimate. Despite that, analysts still view the stock as a Moderate Buy with a consensus target price of $23.82.
REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) insider Steve Pakola sold 2,161 shares of the business's stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total transaction of $29,476.04. Following the transaction, the insider directly owned 213,009 shares in the company, valued at $2,905,442.76. This trade represents a 1.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Steve Pakola also recently made the following trade(s):
- On Monday, June 29th, Steve Pakola sold 19,608 shares of REGENXBIO stock. The shares were sold at an average price of $11.04, for a total transaction of $216,472.32.
- On Wednesday, July 1st, Steve Pakola sold 36,725 shares of REGENXBIO stock. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50.
- On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The stock was sold at an average price of $11.02, for a total transaction of $168,705.18.
REGENXBIO Stock Performance
Shares of RGNX opened at $14.19 on Tuesday. The company has a 50-day simple moving average of $8.40 and a 200-day simple moving average of $9.91. REGENXBIO Inc. has a 52 week low of $5.45 and a 52 week high of $16.19. The firm has a market capitalization of $733.47 million, a P/E ratio of -2.55 and a beta of 0.90.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.36). REGENXBIO had a negative net margin of 330.23% and a negative return on equity of 232.50%. The firm had revenue of $6.39 million for the quarter, compared to the consensus estimate of $25.84 million. As a group, equities analysts forecast that REGENXBIO Inc. will post -3.69 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on RGNX shares. Barclays decreased their price target on shares of REGENXBIO from $37.00 to $12.00 and set an "overweight" rating on the stock in a research note on Friday, May 15th. Robert W. Baird raised their price objective on shares of REGENXBIO from $27.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, June 22nd. Bank of America decreased their target price on shares of REGENXBIO from $25.00 to $14.00 and set a "buy" rating on the stock in a research report on Friday, May 15th. HC Wainwright reissued a "buy" rating and issued a $26.00 price target on shares of REGENXBIO in a research report on Wednesday, July 1st. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of REGENXBIO in a report on Monday, June 8th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, REGENXBIO currently has an average rating of "Moderate Buy" and a consensus target price of $23.82.
Get Our Latest Stock Analysis on REGENXBIO
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its stake in shares of REGENXBIO by 2,247.7% in the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company's stock valued at $4,437,000 after purchasing an additional 594,161 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in REGENXBIO by 64.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company's stock valued at $16,709,000 after purchasing an additional 454,977 shares during the last quarter. Invenomic Capital Management LP bought a new position in REGENXBIO during the 3rd quarter valued at about $4,120,000. Integral Health Asset Management LLC boosted its position in REGENXBIO by 57.1% in the third quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock valued at $10,615,000 after buying an additional 400,000 shares in the last quarter. Finally, State Street Corp grew its stake in REGENXBIO by 15.2% during the fourth quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company's stock worth $32,929,000 after buying an additional 301,858 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors and hedge funds.
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO's pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.
In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
